OCC members praise FDA approval of new obesity drug – Belviq

Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years.

"This is a tremendous step forward in addressing our most pressing health problem. Healthcare professionals now have a new option to help their patients affected by obesity manage this chronic condition. We are happy to see this latest evidence that the FDA is joining the effort to treat obesity seriously," said Dr. Patrick O'Neil, President of The Obesity Society.

Dr. O'Neil continued, "At the same time, it is important to understand that this medication will not work overnight or by itself. Lifestyle changes and support from qualified professionals are still necessary. This is an obesity medication, not a diet pill."

The OCC supports the FDA's continued dedication to excellence in ensuring the safety and effectiveness of new obesity treatments. With more than 93 million Americans affected by obesity, it is imperative to continue this proactive momentum and forward-thinking approach with all safe and effective therapies for the disease.

"We are very pleased with the FDA's decision. These are serious medications for a serious issue. In order for us to fight this epidemic, the right patients must receive the right treatment from a qualified physician in combination with a diet and exercise program," said Joe Nadglowski, Obesity Action Coalition (OAC) President and CEO.